Ampersand 2018 Limited Partnership is a Private Equity Fund in Massachusetts with $453.55M assets under management, with a minimum investment of $100K. It has 78 beneficial owners. Data from SEC filing.
Company profile
Employees
Incorporated
Location
Fiscal year end
Industry
SEC CIK
AUM ?
$453.55M
Address
Ampersand 2018 Limited Partnership
55 WILLIAM STREET
SUITE 240
WELLESLEY
MA 02481
55 WILLIAM STREET
SUITE 240
WELLESLEY
MA 02481
Phone
781-239-0700
Ownership
| Fund structure | AUM | Fund type |
|---|---|---|
| Ampersand Capital Partners | $2.17B | |
| Ampersand 2001 Companion Fund Limited Partnership | $50.88K | Private Equity Fund |
| Ampersand 2001 Limited Partnership | $543.28K | Private Equity Fund |
| Ampersand 2006 Limited Partnership | $6.13M | Private Equity Fund |
| Ampersand 2011 Limited Partnership | $6.05M | Private Equity Fund |
| Ampersand 2014 Limited Partnership | $152.56M | Private Equity Fund |
| Ampersand 2018 Limited Partnership | $453.55M | Private Equity Fund |
| Ampersand 2020 Limited Partnership | $67.42M | Private Equity Fund |
| Ampersand CF Limited Partnership | $635.8M | Private Equity Fund |
Investment data
Regulatory AUM / Assets Under Management
Calendar
25 May 22
31 Dec 22
Financial reports
No filings
Current reports
No filings
Registration and prospectus
Proxies
No filings
Other
No filings
Ownership
SC 13D/A
INTERPACE BIOSCIENCES / Ampersand 2018 Limited Partnership ownership change
12 Nov 21
SC 13D/A
INTERPACE BIOSCIENCES / Ampersand 2018 Limited Partnership ownership change
18 May 21
SC 13D/A
INTERPACE BIOSCIENCES / Ampersand 2018 Limited Partnership ownership change
19 Jan 21
SC 13D/A
INTERPACE BIOSCIENCES / Ampersand 2018 Limited Partnership ownership change
22 Apr 20
4
Change in insider ownership
17 Jan 20
SC 13D/A
Interpace Biosciences, Inc.
17 Jan 20
4
Change in insider ownership
18 Oct 19
4
Change in insider ownership
15 Oct 19
SC 13D
Interpace Diagnostics Group, Inc.
25 Jul 19
3
Initial statement of insider ownership
25 Jul 19